Navigation Links
Celiac disease vaccine shows promising results in Phase I trial
Date:5/9/2011

The world's first potential vaccine for coeliac disease has shown promising results for treating coeliac disease in a Phase I clinical trial and is expected to move to Phase II trials within the next year.

The Phase I trial undertaken in Melbourne, Australia, evaluated the safety, tolerability and bioactivity of the vaccine Nexvax2, which has been developed for coeliac disease. Coeliac disease is an autoimmune disease caused by an immune reaction to the gluten protein found in wheat, rye and barley.

The three peptides on which the vaccine is based were identified by Dr Bob Anderson from the Walter and Eliza Hall Institute's Immunology division. The vaccine is being further developed by US biotechnology company ImmusanT, of which Dr Anderson is Chief Scientific and Medical Officer. Dr Anderson presented the Phase I trial results on Sunday at the Digestive Disease Week symposium in Chicago, Illinois, US.

"Nexvax2 aims to desensitise patients to the three specific peptides in gluten that we have previously identified as 'toxic' to people with coeliac disease," Dr Anderson said. "Our Phase I study showed that Nexvax2 was safe to use and well tolerated, and importantly, that it had the desired biological response in patients with coeliac disease."

Up to one per cent of the global population is affected by coeliac disease, which is currently only treatable by eliminating gluten from the diet. In people with coeliac disease, immune cells react to gluten and trigger an immune response that damages the lining of the small intestine and inhibits its ability to absorb nutrients from food.

Dr Anderson said the vaccine would be suitable for treating the approximately 90 per cent of coeliac disease patients with the DQ2 genetic form of disease.

"In our Phase I trial, we saw a Nexvax2-specific T-cell response that confirms the desired bioactivity in HLA-DQ2 genotype patients," Dr Anderson said. "We expect the vaccine to
'/>"/>

Contact: Ms Penny Fannin
fannin@wehi.edu.au
61-393-452-345
Walter and Eliza Hall Institute
Source:Eurekalert  

Page: 1 2

Related biology news :

1. New and improved gluten-free foods developed for patients with celiac disease
2. New book from the AGA empowers celiac disease patients to get healthy
3. UM School of Medicine Center for Celiac Research finds rate of celiac disease is growing
4. Quest for genes involved in celiac disease
5. Hidden infections crucial to understanding, controlling disease outbreaks
6. Iron-moving malfunction may underlie neurodegenerative diseases, aging
7. LIAI launches new division to look at novel approaches to heart disease and inflammation
8. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
9. World leaders in infectious diseases convene to discuss emerging global viruses
10. Form of Crohns disease traced to disabled gut cells
11. LSUHSC awarded patent for compound inhibiting cancer and other diseases
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Celiac disease vaccine shows promising results in Phase I trial
(Date:7/11/2014)... Salk Institute for Biological Studies, BGI, and other ... and reliability of the existing targeted gene correction ... which could significantly increased gene-correction efficiency in human ... online in Cell Stell Cell provides ... therapy. , The combination of stem cells and ...
(Date:7/11/2014)... July 11, 2014 The increased risk of kidney ... in resuscitation fluids reflects the mass of HES molecules, ... , official journal of the International Anesthesia Research Society ... the harmful effect of HES on cultured human renal ... Dr Christian Wunder and colleagues of University Hospital Wrzburg, ...
(Date:7/11/2014)... 11, 2014 Research and Markets ... Technology Market - Industry Analysis Size Share Growth Trends ... http://photos.prnewswire.com/prnh/20130307/600769 ... created a need for high level security in both ... authentication such as username and passwords, tokens etc. are ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... Sept. 12, 2013 Taking a page from Chinese ... Institute (TGen) today initiated the first-in-human clinical trial for ... plant known as "Thunder God vine." The ... treatment today at Scottsdale Healthcare,s Virginia G. Piper Cancer ...
... map of the human genome, the cost of sequencing ... has resulted in a tremendous increase in the amount ... community for the advancement of biomedical research. Yet, there ... in ensuring ethical and legal interoperability. In addition, the ...
... America (ESA) is proud to announce the winners ... travel grants, which will help entomology students attend ... this November are funded by USDA-NIFA,s Agriculture ... and Nematodes. The grants were created to provide ...
Cached Biology News:TGen and Scottsdale Healthcare launch Phase I 'Thunder God vine' trial for cancer 2TGen and Scottsdale Healthcare launch Phase I 'Thunder God vine' trial for cancer 3Better sharing of genetic information in human health 2Entomological Society of America names winners of 2013 student travel grants 2Entomological Society of America names winners of 2013 student travel grants 3Entomological Society of America names winners of 2013 student travel grants 4Entomological Society of America names winners of 2013 student travel grants 5Entomological Society of America names winners of 2013 student travel grants 6Entomological Society of America names winners of 2013 student travel grants 7Entomological Society of America names winners of 2013 student travel grants 8
(Date:7/10/2014)... July 10, 2014 OMICS Group’s 5th ... during 18-20 August, 2014 at Double Tree by Hilton ... recent developments in Analytical & Bioanalytical research methods only ... Speaking on this occasion, Dr. Srinubabu Gedela, MD of ... conference is a remarkable one in bringing a unique ...
(Date:7/10/2014)... July 10, 2014 Senior supply chain ... professional associations, addressed the challenges of “Reducing Cost, Lead ... Industries” through strategic sourcing. Describing the partnership of the ... Supply Chain Management Institute ( SCMI) of the ... June 24 at the Kroc Institute of Peace and ...
(Date:7/10/2014)... , July 10, 2014 ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique ... MabNext project BIOCAD develops a number of innovative drugs ... autoimmune diseases. The ceremony took place at the International ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- Tute ... interpretation, today announced an agreement with Lineagen, ... for Lineagen,s NextStep Dx PLUS.  Lineagen, ... and neurological disorders, currently offers FirstStep Dx ... testing service used by healthcare providers as ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... , SAN DIEGO, Jan. 11 Amira ... discovery and early development of new drugs to treat inflammatory ... present a company overview at the 28th Annual J.P. Morgan ... PST on Thursday, January 14, at the Westin St. Francis ...
... 7 ... , ... -- Genedata, a leading provider of advanced software solutions for drug discovery and life science ... experienced unprecedented industry adoption with 7 out of the 25 leading pharmaceutical companies using Screener ...
... German . , Researchers from the Helmholtz-Zentrum ... from Oxford and Bristol Universities, as well as the Rutherford ... nanoscale symmetry hidden in solid state matter. They have measured ... the golden ratio famous from art and architecture. The research ...
Cached Biology Technology:Amira Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference 2Genedata at HCA Announces Banner Year for Genedata Screener at Leading Pharmaceutical Companies 2Genedata at HCA Announces Banner Year for Genedata Screener at Leading Pharmaceutical Companies 3Golden ratio discovered in a quantum world 2Golden ratio discovered in a quantum world 3
Request Info...
supplied with 10x reaction buffer...
... yeast/leuconostoc overproducer ATP: D-hexose 6- ... One unit of HK will ... in 1 min at 25C ... of G6P-DH will oxidize 1 ...
Request Info...
Biology Products: